CAR-T Therapy for Stiff Person Syndrome Nears Approval

Why It Matters

The approval would provide the first disease‑modifying option for SPS patients, shifting treatment from symptomatic relief to immune‑targeted therapy, and could unlock a multi‑hundred‑million‑dollar market for biotech innovators.

Key Takeaways

• Kyverna's CAR-T targets pathogenic B cells in stiff person syndrome.
• SPS currently lacks FDA‑approved therapies, relying on off‑label drugs.
• Phase 1/2 data showed 70% patients achieved symptom reduction.
• FDA’s Fast Track designation accelerates review timeline.
• Potential market estimated at $200 million annually in the U.S.

Pulse Analysis

Stiff person syndrome (SPS) is a rare, disabling autoimmune condition characterized by muscle rigidity and painful spasms. Patients typically rely on off‑label benzodiazepines or baclofen, which only provide symptomatic relief and carry significant side‑effect risks. The absence of FDA‑approved therapies has left a sizable unmet medical need, prompting both clinicians and investors to watch emerging immunotherapies closely.

Kyverna Therapeutics’ CAR‑T platform adapts the cancer‑fighting technology to target the B‑cell clones that generate the autoantibodies driving SPS. In a Phase 1/2 trial, the autologous cell product achieved a 70% response rate, with participants reporting marked reductions in muscle stiffness and improved quality of life. The company has secured Fast Track designation from the FDA, expediting the review process and signaling regulatory confidence in the therapy’s potential to address a high‑unmet‑need indication.

If approved, Kyverna’s therapy could open a new market segment estimated at $200 million annually in the United States alone, attracting interest from larger biotech firms seeking to expand into rare‑disease immunotherapies. The success may also catalyze further CAR‑T adaptations for other autoimmune disorders, reshaping the therapeutic landscape beyond oncology. Investors will likely monitor upcoming regulatory milestones and potential partnership deals that could accelerate global rollout.